Oxford Science Enterprises – For all our tomorrows_News & Media

AboutCEO StatementValuesTeamOxford PartnersShareholdersEnterprisesNewsCareersLabs We build world-changing businesses.Scientific breakthroughs can solve our biggest challenges – from infectious diseases and cancer to cyber security, shortages of natural resources, and rapid climate change. But only when they make it out of the lab.We are Oxford Science Enterprises, the Science Business Builder. We want to help solve the world’s toughest problems for more people, in more places, faster. We particularly focus on four key goals:Enabling people to lead longer, healthier livesProtecting the future of our planetFeeding the world and keeping us safeAccelerating the pace of positive changeWe do this by transforming world-leading science into world-changing businesses. OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Read more Nucleome Therapeutics appoints Phil Boyd as Chief Financial Officer Read more Oxford Science Enterprises Appoints Richard Laxer, Former Chairman and CEO of GE Capital, as a Non-Executive Director Read more Util announces the closing of a seed round Read more Refeyn closes Series B funding round Read more OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR) Read more Vaccitech Announces Notification of Milestone and Royalty Revenue relating to sales of Vaxzevria® Read more Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment Read more PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy Read more PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development Read more First Light achieves world first fusion result, proving unique new target technology Read more New Report Highlights Oxford as the UK’s Leading University for Spinout Creation with Oxford Science Enterprises Named as Most Active Fund Focused Solely on a Single Institution Read more More News Updates Oxford Science Enterprises@OxSciences·16hGreat news to end the week, our enterprise @PepGenTx has rung the Nasdaq opening bell to celebrate its IPO and is now trading on the Nasdaq as $PEPG! ?Congratulations to the entire team! PepGen@PepGenTxToday our team rang the @Nasdaq opening bell to celebrate our #IPO! Watch the ceremony live: https://bit.ly/3wbRDq6 $PEPG Reply on Twitter 1522613033020895234Retweet on Twitter 1522613033020895234Like on Twitter 15226130330208952342Twitter 1522613033020895234Oxford Science Enterprises@OxSciences·18hWe’re excited to announce Sam Hauptmann has joined @OxSciences as an Associate in our Tech team.Sam is joining us for the rest of the year on secondment from Tanarra, a $2.3bn fund based in Australia.Welcome to the team, Sam!#oxford #science #talent Reply on Twitter 1522576807874211842Retweet on Twitter 1522576807874211842Like on Twitter 15225768078742118422Twitter 1522576807874211842Oxford Science Enterprises@OxSciences·5 MayIn case you missed it last week… a Covid-19 vaccine being developed with @SpyBiotech's tech elicited a strong immune response in a pre-clinical study published in @ScienceMagazine.You can read more about the paper here ⬇️:https://bit.ly/3vGahr8#oxford #science #vaccine Reply on Twitter 1522161809557438464Retweet on Twitter 15221618095574384641Like on Twitter 15221618095574384641Twitter 1522161809557438464 Sign up to our quarterly newsletter. Follow us: Oxford Science Enterprises. For all our tomorrows. Connect Academics with great ideas: [email protected] Potential investors or co-investors: [email protected] Address 46 Woodstock Road,Oxford, OX2 6HTUnited Kingdom Privacy PolicyCCTV PolicyTerms of UseWebsite Usage Policy © Oxford Science Enterprises 2022 HomeAboutCEO StatementValuesTeamOxford PartnersShareholdersNewsEnterprisesCareersLabs Academics with great ideas: [email protected] Potential investors or co-investors: [email protected] x Stay up to date Get the latest on cutting edge developments from our enterprises straight to your inbox